Free tool
Drug Trial Radar: Psychiatry
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
14
Recruiting, industry sponsors, Psychiatry, Phase 1
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed482
14 trials
Showing 1 to 14, recently updated first.
Novartis PharmaceuticalsNovartis (NVS)
NCT07908680 · 36 participants (planned) · Start Nov 4, 2026 · Primary completion Mar 6, 2028
Drug: XEP527; Placebo · For: Schizophrenia
Sites: Bentonville, Arkansas
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT07615426 · 64 participants (planned) · Start Mar 2, 2026 · Primary completion Jun 21, 2027
Drug: Aticaprant; Placebo · For: Schizophrenia
Sites: Garden Grove, California; Atlanta, Georgia; Chicago, Illinois · 8 sites in all
Leal Therapeutics, IncIndustry
NCT07734493 · 90 participants (planned) · Start Aug 3, 2026 · Primary completion Mar 2027
Drug: LTX-001 once daily; Placebo and 1 more · For: Schizophrenia
Sites: Little Rock, Arkansas; Los Alamitos, California; DeLand, Florida · 10 sites in all
Proniras CorporationIndustry
NCT06538558 · 40 participants (planned) · Start Oct 16, 2024 · Primary completion Oct 14, 2027
Drug: Tezampanel; Placebo · For: Opioid Use Disorder
Sites: Indianapolis, Indiana
AbbVieAbbVie (ABBV)
NCT07071532 · 20 participants (planned) · Start Aug 20, 2026 · Primary completion Feb 2027
Drug: ABBV-932; Itraconazole · For: Bipolar Disorder
Sites: Los Alamitos, California; Grayslake, Illinois
- Evaluate Pharmacokinetics, Safety, and Tolerability of AX251 LAI in Patients With SchizophreniaRecruiting
Anxo Pharmaceutical Co., Ltd.Industry
NCT07484204 · 48 participants (planned) · Start Sep 14, 2026 · Primary completion Jul 2028
Drug: AX251 LAI 45 mg; AX251 LAI 90 mg and 2 more · For: Schizophrenia
Sites: Ahmedabad, India; Gandhinagar, India; Nagar, India · 4 sites in all
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07061288 · 131 participants (planned) · Start Sep 3, 2025 · Primary completion Jun 21, 2027
Drug: KarXT · For: Schizophrenia
Sites: Los Alamitos, California; Hollywood, Florida; Miami Lakes, Florida · 8 sites in all
Vigonvita Life SciencesIndustry
NCT06504290 · 40 participants (planned) · Start Jul 16, 2024 · Primary completion Oct 1, 2026
Drug: VV119 Placebo (in healthy adult subjects); VV119 (in healthy adult subjects) and 2 more · For: Schizophrenia
Sites: Beijing, China; Xi’an, China · 4 sites in all
- Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar DisorderPivotal-lookingRecruiting
BioXcel Therapeutics IncIndustry
NCT05025605 · 140 participants (planned) · Start Aug 27, 2021 · Primary completion Jul 31, 2027
Drug: BXCL501 80 Micrograms; Placebo Film and 2 more · For: Schizophrenia; Schizo-Affective Disorder; Schizophreniform; Schizophrenic and 2 more
Sites: Anaheim, California; Hialeah, Florida; Atlanta, Georgia · 5 sites in all
Sichuan Kelun Pharmaceutical Co.,Ltd.Industry
NCT06674694 · 56 participants (planned) · Start Apr 10, 2024 · Primary completion Jun 30, 2026
Drug: Brexpiprazole long-acting injection · For: Schizophrenia Disorders
Sites: Beijing, China
Mapi Pharma Ltd.Industry
NCT07185815 · 24 participants (planned) · Start Aug 1, 2025 · Primary completion Dec 31, 2026
Drug: Cariprazine Depot; Cariprazine Depot and 2 more · For: Schizophrenia; Bipolar I Disorder; Major Depressive Disorder
Sites: Ahmedabad, India; Beersheba, Israel; Ness Ziona, Israel · 6 sites in all
NeurosterixIndustry
NCT07344948 · 73 participants (planned) · Start Oct 3, 2025 · Primary completion May 2026
Drug: NTX-253; Placebo · For: Healthy Participants; Schizophrenia Diagnosis
Sites: Los Alamitos, California
Luye Pharma Group Ltd.Industry
NCT07230652 · 40 participants (planned) · Start Aug 20, 2025 · Primary completion Dec 31, 2025
Drug: LY03020; Placebo · For: Schizophrenia; Alzheimer's Disease Psychosis
Sites: Beijing, China
- Right Tools, Right Time, Right Place: Telehealth for Opioid Use Disorder in Vulnerable SettingsRecruiting
Boulder CareIndustry
NCT07169409 · 250 participants (planned) · Start Jun 10, 2025 · Primary completion Aug 2027
Drug: Telemedicine Buprenorphine Treatment · For: Opioid Use Disorder
Sites: Portland, Oregon
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.